120 related articles for article (PubMed ID: 27362767)
1. Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Nozawa H; Ishihara S; Kawai K; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Hata K; Watanabe T
Oncology; 2016; 91(3):127-34. PubMed ID: 27362767
[TBL] [Abstract][Full Text] [Related]
2. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Komatsu Y; Ishioka C; Shimada K; Yamada Y; Gamoh M; Sato A; Yamaguchi T; Yuki S; Morita S; Takahashi S; Goto R; Kurihara M
BMC Cancer; 2015 Sep; 15():626. PubMed ID: 26353772
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
[TBL] [Abstract][Full Text] [Related]
4. Determination of circulating tumor cells for prediction of recurrent colorectal cancer progression.
Kawahara H; Watanabe K; Toyama Y; Yanagisawa S; Kobayashi S; Yanaga K
Hepatogastroenterology; 2012 Oct; 59(119):2115-8. PubMed ID: 22328299
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
6. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
8. [Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Doi T; Ohtsu A
Nihon Rinsho; 2003 Sep; 61 Suppl 7():368-73. PubMed ID: 14574915
[No Abstract] [Full Text] [Related]
9. Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer.
Kim G; Jung EJ; Ryu CG; Hwang DY
Yonsei Med J; 2013 Jan; 54(1):116-22. PubMed ID: 23225807
[TBL] [Abstract][Full Text] [Related]
10. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
[TBL] [Abstract][Full Text] [Related]
11. Low-dose chemotherapy with leucovorin plus 5-fluorouracil for colorectal cancer can maintain host immunity.
Kobayashi R; Yoshimatsu K; Yokomizo H; Katsube T; Ogawa K
Anticancer Res; 2007; 27(1B):675-9. PubMed ID: 17348459
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
Tokunaga Y; Sasaki H; Matsueda S
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1127-31. PubMed ID: 21772096
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Tomoda M; Kawahara H; Watanabe K; Enomoto H; Akiba T; Yanaga K
Anticancer Res; 2014 Jan; 34(1):191-4. PubMed ID: 24403461
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
Kim MS; Chung M; Ahn JB; Kim CW; Cho MS; Shin SJ; Baek SJ; Hur H; Min BS; Baik SH; Kim NK
J Surg Oncol; 2014 Aug; 110(2):214-21. PubMed ID: 24668581
[TBL] [Abstract][Full Text] [Related]
15. [Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital].
Hosoda K; Aoki M; Kido H; Natsu K; Tamura H; Kojima M; Amemiya T; Kamoshida T
Gan To Kagaku Ryoho; 2010 May; 37(5):841-5. PubMed ID: 20495313
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
Yoshida M; Goto M; Kii T; Nishitani H; Kawabe S; Kuwakado S; Asaishi K; Miyamoto T; Higuchi K
Digestion; 2013; 87(1):59-64. PubMed ID: 23343971
[TBL] [Abstract][Full Text] [Related]
18. Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
Ma J; Yang QL; Ling Y
BMC Cancer; 2017 Feb; 17(1):132. PubMed ID: 28196490
[TBL] [Abstract][Full Text] [Related]
19. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
[TBL] [Abstract][Full Text] [Related]
20. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
